KRAS latecomer Roche draws cautious comparisons to Amgen, Mirati in early data
On a quest not just to catch up with, but leapfrog, Amgen and Mirati in the KRAS race, Roche has released early monotherapy data on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
